A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of b-cell non-hodgkins lymphoma

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6820-6829

  Natarajan, Arutselvan ^a   Hackel, Benjamin J ^a   Gambhir, Sanjiv Sam ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COPPER 64; DO FN3 CD20 CU 64; DO RITUXIMAB CU 64; TETRAXETAN; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; FIBRONECTINS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890670507     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0626     Document Type: Article

References (47)

1. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421-8. (Pubitemid 46218853)
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4. (Pubitemid 24272191)
3. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988;85:208-12.
4. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161:3242-8.
5. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71. (Pubitemid 43939148)
6. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340-8. (Pubitemid 36302079)
7. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunother-apy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282-90.
8. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem 2010;21:947-54.
9. Nordberg E, Orlova A, Friedman M, Tolmachev V, Stahl S, Nilsson FY, et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 2008;19:853-7. (Pubitemid 351802651)
10. Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613-22.
11. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, et al. Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing avb3 Integrin. J Nucl Med 2010;51:251-8.
12. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009;69:2435-42.
13. Gainkam LOT, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/Micro-CT. J Nucl Med 2008;49:788-95. (Pubitemid 351717545)
14. Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10:167-75.
15. Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor avb3-integrin expression. J Nucl Med 2004;45:1776-83. (Pubitemid 47618490)
16. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850-8. (Pubitemid 46798960)
17. Niu G, Li Z, Xie J, Le Q-T, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009;50:1116-23.
18. Niu G, Sun X, Cao Q, Courter D, Koong A, Le Q-T, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010;16:2095-105.
19. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Rau-bitschek AA, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9. (Pubitemid 40022142)
20. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011;24:3-9.
21. Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci 2007;104:6632-7. (Pubitemid 47175552)
22. Hackel BJ, Kimura RH, Gambhir SS. Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology 2012;263:179-88.
23. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
24. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71.
25. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605.
26. Hackel BJ, Ackerman ME, Howland SW, Wittrup KD. Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol 2010;401:84-96.
27. Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 2007;352:95-109.
28. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011;17:363-71.
29. Hackel BJ, Kapila A, Wittrup KD. Picomolar affinityfibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008;381:1238-52.
30. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 2000;27:93-100. (Pubitemid 30099621)
31. Natarajan A, Gowrishankar G, Nielsen CH, Wang S, Iagaru A, Goris ML, et al. Positron emission tomography of (64)Cu-DOTA-rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol 2012;14:608-16.
32. Lu SX, Takach EJ, Solomon M, Zhu Q, Law SJ, Hsieh FY. Massspectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J Pharm Sci 2005;94:788-97. (Pubitemid 40577311)
33. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immu-notherapy. J Immunol 2005;174:817-26. (Pubitemid 40094277)
34. Natarajan A, Habte F, Gambhir SS. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjugate Chem 2012;23:1221-29.
35. Loening AM, Gambhir SS. AMIDE: a free software tool for multimod-ality medical image analysis. Mol Imaging 2003;2:131-7.
36. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2011;16:277-306.
37. Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 2009;50: 1500-8.
38. Bakir MA, Eccles S, Babich JW, Aftab N, Styles J, Dean CJ, et al. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992;33: 2154-60.
39. Jekunen A, Kairemo K, Karnani P. In vivo modulators of antibody kinetics. Acta Oncol 1996;35:267-71. (Pubitemid 26201746)
40. Bloom L, Calabro V. FN3: a new protein scaffold reaches the clinic. Drug Discovery Today 2009;14:949-55.
41. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66. (Pubitemid 44356635)
42. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007;13:3-16. (Pubitemid 46085298)
43. Natarajan A, Habte F, Liu H, Sathirachinda A, Hu X, Cheng Z, et al. Evaluation of Zr-rituximab tracer by cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL. Mol Imaging Biol 2013;15:468-75.
44. Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 2010;23:243-9.
45. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175-83. (Pubitemid 43939045)
46. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18) F-FDG-pet with (67)gallium scintigraphy in the evaluation of lympho-ma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652-9. (Pubitemid 47106156)
47. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 2008;35: 1245-55. (Pubitemid 352000767)